Indeed, both infigratinib and erdafitinib were shown to be efficacious in UPS cell lines derived from a subset of patients carrying FGFR2 amplification, while erdafitinib also reduced in vivo growth of tumours formed by one of the FGFR2 amplified cell lines [42]. This evidence concerns the gene FGFR2 and neoplasm.